Please upgrade your browser.
Argos Therapeutics today announced that results from its Arcelis immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
The cost of cancer can be devastating to Canadians, because the medications they often need to take at home can wipe out their life savings, says the Canadian Cancer Society in a call for more coverage of "catastrophic" drugs.
To investigate the efficacy of simplified (two- or three-tiered) Fuhrman grading systems as prognostic indicators in clear-cell renal cell carcinoma (RCC).
In this article, we will discuss the current status of imaging in patients with hematuria of urologic origin
Health insurers say they plan to raise premiums for some Americans as a direct result of the health overhaul in coming weeks, complicating Democrats' efforts to trumpet their signature achievement before the midterm elections.
Education and support for families dealing with renal malignancies
We conducted a phase I/II trial to determine the safety and efficacy of infliximab in combination with sorafenib in patients with advanced RCC.
Many studies have demonstrated the strong correlation between HA accumulation and presence of malignancy in numerous solid tumor types, including genitourinary cancers.
|Powered by NeonCRM|